PT1913939T - Formulações para utilização em dispositivos inalatórios - Google Patents
Formulações para utilização em dispositivos inalatóriosInfo
- Publication number
- PT1913939T PT1913939T PT71205918T PT07120591T PT1913939T PT 1913939 T PT1913939 T PT 1913939T PT 71205918 T PT71205918 T PT 71205918T PT 07120591 T PT07120591 T PT 07120591T PT 1913939 T PT1913939 T PT 1913939T
- Authority
- PT
- Portugal
- Prior art keywords
- particles
- formulations
- inhaler devices
- excipient
- milling
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00113608 | 2000-06-27 | ||
GB0029263A GB0029263D0 (en) | 2000-11-30 | 2000-11-30 | Method of making particles for use in a pharmaceutical composition |
PCT/GB2001/001732 WO2001078694A2 (en) | 2000-04-17 | 2001-04-17 | Formulations for use in inhaler devices |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1913939T true PT1913939T (pt) | 2017-07-19 |
Family
ID=26071085
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT01947612T PT1296651E (pt) | 2000-06-27 | 2001-06-27 | Método para fazer partículas para serem usadas numa composição farmacêutica |
PT71205918T PT1913939T (pt) | 2000-06-27 | 2001-06-27 | Formulações para utilização em dispositivos inalatórios |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT01947612T PT1296651E (pt) | 2000-06-27 | 2001-06-27 | Método para fazer partículas para serem usadas numa composição farmacêutica |
Country Status (11)
Country | Link |
---|---|
US (4) | US7744855B2 (pt) |
EP (3) | EP2266549B1 (pt) |
KR (1) | KR100949539B1 (pt) |
CN (1) | CN100551358C (pt) |
AT (1) | ATE378039T1 (pt) |
DK (1) | DK1913939T3 (pt) |
ES (2) | ES2292598T3 (pt) |
HK (1) | HK1056115A1 (pt) |
IL (2) | IL153705A0 (pt) |
PT (2) | PT1296651E (pt) |
WO (1) | WO2002000197A1 (pt) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9501841D0 (en) * | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
GB9515182D0 (en) * | 1995-07-24 | 1995-09-20 | Co Ordinated Drug Dev | Improvements in and relating to powders for use in dry powder inhalers |
GB0009468D0 (en) * | 2000-04-17 | 2000-06-07 | Vectura Ltd | Improvements in or relating to formulations for use in inhaler devices |
PE20011227A1 (es) * | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
GB0009469D0 (en) * | 2000-04-17 | 2000-06-07 | Vectura Ltd | Improvements in or relating to formalities for use in inhaler devices |
IL153705A0 (en) | 2000-06-27 | 2003-07-06 | Vectura Ltd | Method of making particles for use in a pharmaceutical composition |
DE60140268D1 (de) * | 2000-11-30 | 2009-12-03 | Vectura Ltd | Partikel zur verwendung in einer pharmazeutischen zusammensetzung |
DK1920763T3 (da) | 2000-11-30 | 2014-07-07 | Vectura Ltd | Farrmaceutiske præparater til inhalation |
GB0208742D0 (en) * | 2002-04-17 | 2002-05-29 | Bradford Particle Design Ltd | Particulate materials |
EP1487417A4 (en) | 2001-09-17 | 2010-03-17 | Glaxo Group Ltd | DRY POWDER DRUG FORMULATIONS |
CN102688224A (zh) * | 2003-04-14 | 2012-09-26 | 维克特拉有限公司 | 用于提高剂量效率的药物组合物和装置 |
US20060147389A1 (en) * | 2004-04-14 | 2006-07-06 | Vectura Ltd. | Devices and pharmaceutical compositions for enhancing dosing efficiency |
US7094545B2 (en) | 2003-04-30 | 2006-08-22 | Ferring Bv | Pharmaceutical composition as solid dosage form and method for manufacturing thereof |
MXPA05012821A (es) * | 2003-05-28 | 2006-02-13 | Nektar Therapeutics | Formulacion farmaceutica que comprende un agente activo insoluble en agua. |
JP2009513529A (ja) * | 2003-07-11 | 2009-04-02 | グラクソ グループ リミテッド | ステアリン酸マグネシウムを含む医薬製剤 |
DE60301351T2 (de) | 2003-07-25 | 2006-01-19 | Ferring B.V. | Pharmazeutische Desmopressin-Zubereitung als feste Darreichungsform und Methode zu ihrer Herstellung |
GB0327723D0 (en) | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
US20070043030A1 (en) * | 2003-09-15 | 2007-02-22 | Vectura Limited | Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation |
GB0321607D0 (en) * | 2003-09-15 | 2003-10-15 | Vectura Ltd | Manufacture of pharmaceutical compositions |
GB0324918D0 (en) * | 2003-10-24 | 2003-11-26 | Glaxo Group Ltd | Composition |
US7018653B2 (en) | 2003-12-29 | 2006-03-28 | Ferring B.V. | Method for preparing solid dosage form of desmopressin |
DE102004011512B4 (de) * | 2004-03-08 | 2022-01-13 | Boehringer Ingelheim Vetmedica Gmbh | Pharmazeutische Zubereitung enthaltend Pimobendan |
EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
US8980894B2 (en) * | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
GB0409703D0 (en) | 2004-04-30 | 2004-06-02 | Vectura Ltd | Pharmaceutical compositions |
GB0425758D0 (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
GB0426301D0 (en) * | 2004-11-30 | 2004-12-29 | Vectura Ltd | Pharmaceutical formulations |
EP1848444B1 (en) | 2005-02-10 | 2016-11-09 | Glaxo Group Limited | Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom |
ITMI20051999A1 (it) | 2005-10-21 | 2007-04-22 | Eratech S R L | Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita' |
AU2007264418B2 (en) | 2006-06-30 | 2012-05-03 | Iceutica Pty Ltd | Methods for the preparation of biologically active compounds in nanoparticulate form |
GB0613161D0 (en) | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
EP1920785A1 (en) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
SI2197429T1 (sl) * | 2007-09-03 | 2016-09-30 | Nanotherapeutics, Inc. | Sestavki iz delcev za vnos slabo topnih zdravil |
EP2080508A1 (en) | 2008-01-15 | 2009-07-22 | CHIESI FARMACEUTICI S.p.A. | Dry powder formulation comprising an anticholinergic drug |
WO2009142852A2 (en) | 2008-05-22 | 2009-11-26 | 3M Innovative Properties Company | Process for manufacturing flowable powder drug compositions |
US9956170B2 (en) | 2008-06-26 | 2018-05-01 | 3M Innovative Properties Company | Dry powder pharmaceutical compositions for pulmonary administration, and methods of manufacturing thereof |
EP2309984B1 (en) | 2008-07-02 | 2018-04-11 | 3M Innovative Properties Company | Method of making a dry powder pharmaceutical composition |
PL2370070T3 (pl) | 2008-11-25 | 2014-02-28 | Boehringer Ingelheim Vetmedica Gmbh | Pimobendan do zastosowania w leczeniu kardiomiopatii przerostowej u kotów |
CA2754691C (en) | 2009-03-26 | 2019-07-30 | Pulmatrix, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
US20120101077A1 (en) * | 2009-04-24 | 2012-04-26 | Schering Corporation | Agglomerate formulations useful in dry powder inhalers |
NZ595984A (en) * | 2009-04-24 | 2014-04-30 | Iceutica Pty Ltd | Production of encapsulated nanoparticles at commercial scale |
KR101743847B1 (ko) | 2009-04-24 | 2017-06-05 | 아이슈티카 피티와이 리미티드 | 신규 인도메타신 제제 |
GB0921481D0 (en) | 2009-12-08 | 2010-01-20 | Vectura Ltd | Process and product |
CA2784207C (en) * | 2009-12-14 | 2018-06-05 | Chiesi Farmaceutici S.P.A. | Antibiotic microparticles for inhalation |
US9228785B2 (en) | 2010-05-04 | 2016-01-05 | Alexander Poltorak | Fractal heat transfer device |
PE20130282A1 (es) | 2010-06-22 | 2013-03-25 | Chiesi Farma Spa | Formulacion en polvo seca que comprende una droga antimuscarinica |
ME03022B (me) | 2010-08-03 | 2018-10-20 | Chiesi Farm Spa | Formulacija suvog praha која ukuučuje inhibitor fosfodiesteraze |
EP2464346A1 (en) | 2010-08-30 | 2012-06-20 | Pulmatrix, Inc. | Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder |
CN103200938B (zh) | 2010-08-30 | 2018-07-31 | 普马特里克斯营业公司 | 干燥粉末配方及用于治疗肺部疾病的方法 |
AU2011314007B2 (en) | 2010-09-29 | 2017-01-19 | Pulmatrix, Inc. | Cationic dry powders |
EP4008326A1 (en) | 2010-09-29 | 2022-06-08 | Pulmatrix Operating Company, Inc. | Monovalent metal cation dry powders for inhalation |
TW201304822A (zh) | 2010-11-15 | 2013-02-01 | Vectura Ltd | 組成物及用途 |
TW201306847A (zh) | 2010-11-30 | 2013-02-16 | Vectura Ltd | 組成物及用途 |
CA2865972C (en) | 2012-02-29 | 2022-01-04 | Pulmatrix, Inc. | Inhalable dry powders |
US10398705B2 (en) | 2012-03-15 | 2019-09-03 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof |
CA2907566C (en) | 2013-04-01 | 2023-08-22 | Pulmatrix, Inc. | Tiotropium dry powders |
ITMI20130572A1 (it) * | 2013-04-10 | 2014-10-11 | Eratech Srl | Composizione comprendente almeno due polveri secche ottenute per spray dry per aumentare la stabilita' della formulazione |
ITMI20130571A1 (it) | 2013-04-10 | 2014-10-11 | Zambon Spa | Composizione farmaceutica contenente budesonide e formoterolo |
HUE054186T2 (hu) | 2013-07-19 | 2021-08-30 | Boehringer Ingelheim Vetmedica Gmbh | Éterezett ciklodextrin-származékokat tartalmazó, tartósított, folyékony, vizes gyógyászati készítmény |
KR102308973B1 (ko) | 2013-12-04 | 2021-10-08 | 베링거잉겔하임베트메디카게엠베하 | 개선된 피모벤단의 약제학적 조성물 |
WO2015127315A1 (en) | 2014-02-20 | 2015-08-27 | Otitopic Inc. | Dry powder formulations for inhalation |
US9526734B2 (en) | 2014-06-09 | 2016-12-27 | Iceutica Pty Ltd. | Formulation of meloxicam |
PL3179986T3 (pl) * | 2014-07-31 | 2023-06-26 | Vectura Inc. | Suche formulacje w proszku do inhalacji |
AU2015330010A1 (en) | 2014-10-08 | 2017-04-27 | Zambon S.P.A. | Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation |
JP6684275B2 (ja) * | 2014-10-08 | 2020-04-22 | ザンボン ソシエタ ペル アチオニ | ブデソニド及びホルモテロールを含有する医薬組成物 |
DK3212212T3 (da) | 2014-10-31 | 2020-12-21 | Univ Monash | Pulverformulering |
EP3340982B1 (en) | 2015-08-26 | 2021-12-15 | Achillion Pharmaceuticals, Inc. | Compounds for treatment of immune and inflammatory disorders |
AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
RU2018145364A (ru) | 2016-06-27 | 2020-07-28 | Ачиллион Фармасьютикалс, Инк. | Хиназолиновые и индольные соединения для лечения медицинских нарушений |
EP3485215B1 (en) | 2016-07-12 | 2023-06-07 | Alexander Poltorak | System and method for maintaining efficiency of a heat sink |
KR20210018199A (ko) | 2018-03-26 | 2021-02-17 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스의 분해를 위한 세레블론 결합제 |
US20230022157A1 (en) | 2018-08-20 | 2023-01-26 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement factor d medical disorders |
EP3866773A4 (en) | 2018-10-16 | 2022-10-26 | Georgia State University Research Foundation, Inc. | CARBON MONOXIDE PRODRUGS FOR THE TREATMENT OF MEDICAL CONDITIONS |
KR20200078162A (ko) | 2018-12-21 | 2020-07-01 | 한미약품 주식회사 | 흡입 제형용 건조 분말 및 이의 제조방법 |
KR102330428B1 (ko) | 2019-10-14 | 2021-11-24 | 한미약품 주식회사 | 흡입 제형용 건조 분말 및 이의 제조방법 |
WO2023187393A1 (en) | 2022-03-31 | 2023-10-05 | Hovione Scientia Limited | Inhalation composite and carrier based formulation combination |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1381872A (en) | 1971-06-22 | 1975-01-29 | Fisons Ltd | Pharmaceutical compositions for inhalation |
US4349542A (en) | 1979-06-08 | 1982-09-14 | National Research Development Corporation | Mixture containing active ingredient and dendritic crystalline sugar for tableting |
IT1204826B (it) * | 1986-03-04 | 1989-03-10 | Chiesi Farma Spa | Composizioni farmaceutiche per inalazione |
SE8603812D0 (sv) | 1986-09-12 | 1986-09-12 | Draco Ab | Administration of liposomes to mammals |
DE3917617A1 (de) | 1989-05-31 | 1990-12-06 | Boehringer Ingelheim Kg | Mikronisierte bioabbaubare partikel, verfahren zur ihrer herstellung und ihre verwendung |
US5376386A (en) * | 1990-01-24 | 1994-12-27 | British Technology Group Limited | Aerosol carriers |
WO1993025193A1 (en) * | 1992-06-12 | 1993-12-23 | Teijin Limited | Pharmaceutical preparation for intra-airway administration |
GB2269992A (en) * | 1992-08-14 | 1994-03-02 | Rh Ne Poulenc Rorer Limited | Powder inhalation formulations |
IS1796B (is) * | 1993-06-24 | 2001-12-31 | Ab Astra | Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband |
US5506203C1 (en) * | 1993-06-24 | 2001-02-06 | Astra Ab | Systemic administration of a therapeutic preparation |
AUPM414394A0 (en) * | 1994-02-28 | 1994-03-24 | Voxson International Pty. Limited | Multi-mode communications system |
GB9501841D0 (en) * | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
US5612053A (en) * | 1995-04-07 | 1997-03-18 | Edward Mendell Co., Inc. | Controlled release insufflation carrier for medicaments |
AU5655296A (en) | 1995-05-09 | 1996-11-29 | Colorcon Limited | Electrostatic coating |
GB9515182D0 (en) | 1995-07-24 | 1995-09-20 | Co Ordinated Drug Dev | Improvements in and relating to powders for use in dry powder inhalers |
GB9526495D0 (en) | 1995-12-23 | 1996-02-28 | Knoll Ag | Therapeutic agents |
US5985309A (en) * | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US5955023A (en) * | 1996-11-27 | 1999-09-21 | Callutech, Llc | Method of forming composite particle products |
PT954282E (pt) * | 1997-01-16 | 2005-06-30 | Massachusetts Inst Technology | Preparacao de particulas para inalacao |
US6565885B1 (en) * | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
NZ506289A (en) * | 1998-03-16 | 2004-12-24 | Nektar Therapeutics | Aerosolized active agent delivery to the lungs at a flow rate of less than 17 liters per minute |
ES2219000T3 (es) | 1998-03-26 | 2004-11-16 | Fujisawa Pharmaceutical Co., Ltd. | Preparacion de liberacion sostenida de un compuesto macrolido. |
US6428814B1 (en) * | 1999-10-08 | 2002-08-06 | Elan Pharma International Ltd. | Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
HU226164B1 (en) | 1998-11-13 | 2008-05-28 | Jagotec Ag | Use of magnesium stearate in dry powder compositions suitable for inhalation and compositions suitable for inhalation |
GB9826783D0 (en) * | 1998-12-04 | 1999-01-27 | Scherer Ltd R P | Inhalation powders |
GB9827145D0 (en) * | 1998-12-09 | 1999-02-03 | Co Ordinated Drug Dev | Improvements in or relating to powders |
IT1309592B1 (it) | 1999-03-05 | 2002-01-24 | Chiesi Farma Spa | Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e |
ATE289825T1 (de) | 1999-04-21 | 2005-03-15 | 1355540 Ontario Inc | Methacoline oder histamine formulierungen zur feststellung von asthma |
PT1666028E (pt) * | 1999-10-29 | 2010-06-15 | Novartis Ag | Composições de pós anidros com melhor dispersividade |
PE20011227A1 (es) * | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
GB0009468D0 (en) | 2000-04-17 | 2000-06-07 | Vectura Ltd | Improvements in or relating to formulations for use in inhaler devices |
GB0009469D0 (en) * | 2000-04-17 | 2000-06-07 | Vectura Ltd | Improvements in or relating to formalities for use in inhaler devices |
IL153705A0 (en) * | 2000-06-27 | 2003-07-06 | Vectura Ltd | Method of making particles for use in a pharmaceutical composition |
DK1920763T3 (da) * | 2000-11-30 | 2014-07-07 | Vectura Ltd | Farrmaceutiske præparater til inhalation |
DE60140268D1 (de) | 2000-11-30 | 2009-12-03 | Vectura Ltd | Partikel zur verwendung in einer pharmazeutischen zusammensetzung |
US6966990B2 (en) | 2002-10-11 | 2005-11-22 | Ferro Corporation | Composite particles and method for preparing |
US20060147389A1 (en) | 2004-04-14 | 2006-07-06 | Vectura Ltd. | Devices and pharmaceutical compositions for enhancing dosing efficiency |
US9192915B2 (en) * | 2008-05-10 | 2015-11-24 | Brigham Young University | Porous composite particulate materials, methods of making and using same, and related apparatuses |
EP2528978B1 (de) * | 2010-01-27 | 2013-11-13 | Basf Se | Beschichtungsmittel enthaltend kompositpartikel |
US8491908B2 (en) * | 2010-06-01 | 2013-07-23 | Canon Kabushiki Kaisha | Composite particle, contrast agent for photoacoustic imaging, and method for producing the composite particle |
-
2001
- 2001-06-27 IL IL15370501A patent/IL153705A0/xx active IP Right Grant
- 2001-06-27 KR KR1020027017595A patent/KR100949539B1/ko active IP Right Grant
- 2001-06-27 ES ES01947612T patent/ES2292598T3/es not_active Expired - Lifetime
- 2001-06-27 EP EP10185471.9A patent/EP2266549B1/en not_active Revoked
- 2001-06-27 DK DK07120591.8T patent/DK1913939T3/en active
- 2001-06-27 EP EP01947612.6A patent/EP1296651B2/en not_active Expired - Lifetime
- 2001-06-27 WO PCT/GB2001/002860 patent/WO2002000197A1/en active IP Right Grant
- 2001-06-27 AT AT01947612T patent/ATE378039T1/de active
- 2001-06-27 PT PT01947612T patent/PT1296651E/pt unknown
- 2001-06-27 ES ES07120591.8T patent/ES2632461T3/es not_active Expired - Lifetime
- 2001-06-27 US US10/312,488 patent/US7744855B2/en not_active Expired - Fee Related
- 2001-06-27 EP EP07120591.8A patent/EP1913939B1/en not_active Expired - Lifetime
- 2001-06-27 PT PT71205918T patent/PT1913939T/pt unknown
- 2001-06-27 CN CNB018118887A patent/CN100551358C/zh not_active Expired - Lifetime
-
2002
- 2002-12-26 IL IL153705A patent/IL153705A/en unknown
-
2003
- 2003-09-26 HK HK03106950A patent/HK1056115A1/xx not_active IP Right Cessation
-
2010
- 2010-05-18 US US12/782,283 patent/US9351928B2/en not_active Expired - Lifetime
-
2016
- 2016-05-02 US US15/144,770 patent/US20160243039A1/en not_active Abandoned
-
2017
- 2017-10-31 US US15/799,521 patent/US10561613B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP2266549A2 (en) | 2010-12-29 |
KR20030051439A (ko) | 2003-06-25 |
HK1056115A1 (en) | 2004-02-06 |
DK1913939T3 (en) | 2017-09-18 |
ATE378039T1 (de) | 2007-11-15 |
EP2266549B1 (en) | 2019-08-07 |
ES2292598T3 (es) | 2008-03-16 |
EP1296651B2 (en) | 2019-07-17 |
EP2266549A3 (en) | 2012-01-18 |
EP1296651A1 (en) | 2003-04-02 |
EP1296651B1 (en) | 2007-11-14 |
CN100551358C (zh) | 2009-10-21 |
IL153705A0 (en) | 2003-07-06 |
PT1296651E (pt) | 2008-02-12 |
US20030162835A1 (en) | 2003-08-28 |
EP1913939B1 (en) | 2017-05-31 |
US20100285142A1 (en) | 2010-11-11 |
US20180055772A1 (en) | 2018-03-01 |
IL153705A (en) | 2011-02-28 |
KR100949539B1 (ko) | 2010-03-25 |
ES2632461T3 (es) | 2017-09-13 |
WO2002000197A1 (en) | 2002-01-03 |
US10561613B2 (en) | 2020-02-18 |
US9351928B2 (en) | 2016-05-31 |
EP1913939A1 (en) | 2008-04-23 |
US7744855B2 (en) | 2010-06-29 |
CN1438875A (zh) | 2003-08-27 |
US20160243039A1 (en) | 2016-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1913939T (pt) | Formulações para utilização em dispositivos inalatórios | |
HK1154347A1 (zh) | 製備用於藥物組合物的顆粒的方法 | |
HK1077195A1 (en) | Modafinil pharmaceutical compositions | |
WO2005025536A8 (en) | Dry powder composition comprising co-jet milled particles for pulmonary inhalation | |
HUP0300593A3 (en) | Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets | |
ATE271383T1 (de) | Pulverformulierung zur inhalation | |
MXPA03011793A (es) | Formulaciones de interferon. | |
HUS1800013I1 (hu) | Cladribine tartalmú orális gyógyászati készítmény | |
SE0103211D0 (sv) | New formulations and use thereof | |
AU3102597A (en) | Method for providing dense particle compositions for use in transdermal particle delivery | |
DE60128902D1 (de) | Formulierungen zur verwendung in inhalationsvorrichtungen | |
HK1037525A1 (en) | Milling process for the production of finely milled medicinal substances | |
WO2002043693A3 (en) | Pharmaceutical compositions for inhalation | |
IL165086A (en) | Pyridyl cyanoguanidines, pharmaceutical compositions comprising them and uses thereof for the preparation of medicaments | |
WO2005123086A3 (en) | Ziprasidone dosage form | |
WO2005030142A3 (en) | Rifalazil formulations | |
AU2001296939A1 (en) | Oral delivery method and composition for solid medications or dietary supplements in the form of solid particles | |
HK1037563A1 (en) | Milling process for the production of finely milled medicinal substances | |
AU2003286617A1 (en) | Calcitonin drug-oligomer conjugates, and uses thereof | |
SI1270576T1 (en) | 3-phenyl-3,7-diazabicyclo(3,3,1)nonanes, process for their preparation and pharmaceutical compositions containing them | |
UA88256C2 (ru) | Фармацевтические композиции модафинила, способ получения композиции модафинила и пероральная дозированная лекарственная форма | |
GEP20033134B (en) | Method for Prevention and Treatment of Brucellosis | |
AU2002259013A1 (en) | Novel methods and compositions for delivering macromolecules to or via the respiratory tract | |
UA49112C2 (uk) | Гепатопротекторний засіб | |
WO2003049668A3 (en) | Method of administering calcium citrate |